目的：观察化疗联合小剂量白介素-2（IL-2）治疗初发急性髓系白血病（AML）的近期疗效及安全性。方法将58例AML患者随机分为观察组（29例）和对照组（29例）。对照组单纯采用化疗，观察组在化疗基础上加用IL-2100万IU/d，14d为1个疗程，2个疗程后评价疗效及不良反应。结果患者对IL-2耐受性良好，观察组完全缓解（CR）率、达CR所需时间与对照组比较差异无统计学意义[62.1% vs 58.6%，（18.5±5.2）d vs（19.2±4.3）d，P>0.05]；观察组Ⅲ、Ⅳ级血液学毒性及感染的发生率均显著低于对照组，差异有统计学意义（P<0.05）。结论化疗联合小剂量IL-2治疗初治急性髓系白血病不能提高CR，但IL-2可降低感染风险，减轻血液学毒性。%ObjectiveTo observe the efficacy and safety of chemotherapy in combination with low-dose interleukin-2 in the treatment of newly diagnosed acute myeloid leukemia,AML.MethodsFifty-eight patients with AML were randomly divided into observation group and control group. The control group was treated only with chemotherapy,the observation group was given chemotherapy based on injection of interleukin-2 1, 000,000IU,14 days for a course of treatment,evaluated the efficacy and adverse reactions after 2 cycles.ResultsIL-2 was well tolerated by the patients. The difference between the two groups in complete remission(CR)rate(62.1% vs 58.6%)and the time acquire to CR[(18.5±5.2) d vs(19.2±4.3)d,P>0.05] was not significant; the incidences of hematological toxicities of gradeⅢ and gradeⅣ,and infections were significantly lower in the observation group. The difference was statistically significant(P<0.05).ConclusionChemotherapy in combination with low-dose interleukin-2 can not increase CR rate in the treatment of AML,but IL-2 can reduce the risk of infection,reducing the hematologic toxicities.
展开▼
